Patents by Inventor Lung-Jr LIN

Lung-Jr LIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12139716
    Abstract: Provided is a composition for simultaneously targeting a nucleic acid sequence and providing intron selection in cells in vitro, ex vivo or in vivo. The composition includes one or more nucleic acid molecules each including an artificial nucleic acid sequence flanked with capping sequences, and Lambda beta protein or a linear or circular vector including a nucleic acid sequence encoding the Lambda beta protein, wherein each of the capping sequences is homologous to a region in a target nucleic acid sequence, and the artificial nucleic acid sequence is an intron sequence. The present disclosure also provides a method for editing a target nucleic acid sequence in cells by introducing the composition into the cells.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 12, 2024
    Inventors: Lung-Jr Lin, Yi-hua Hsu
  • Patent number: 11564908
    Abstract: Provided is a long-acting method for preventing or treating glucose metabolism disorders that includes administering a beta-lactam compound or a pharmaceutically acceptable salt thereof to a subject in need thereof. The method for preventing or treating glucose metabolism disorders has a long-acting effect that lasts more than two days even after medication has been stopped.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: January 31, 2023
    Assignee: GLYCOLYSIS BIOMED CO., LTD.
    Inventors: Feng-Ling Lee, Lung-Jr Lin, Jyh-Shing Hsu, Cheng-Hsien Hsu, Yen-Chun Huang, Ya-Chien Huang, Chun-Tsung Lo, Hui-Fang Liao, Yu-Wen Liu, Yu-Chi Kao
  • Patent number: 11419852
    Abstract: Provided is a long-acting method for preventing or treating glucose metabolism disorders that includes administering a beta-lactam compound or a pharmaceutically acceptable salt thereof to a subject in need thereof. The method for preventing or treating glucose metabolism disorders has a long-acting effect that lasts more than two days even after medication has been stopped.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: August 23, 2022
    Assignee: GLYCOLYSIS BIOMED CO., LTD.
    Inventors: Feng-Ling Lee, Lung-Jr Lin, Jyh-Shing Hsu, Cheng-Hsien Hsu, Yen-Chun Huang, Ya-Chien Huang, Chun-Tsung Lo, Hui-Fang Liao, Yu-Wen Liu, Yu-Chi Kao
  • Patent number: 11033603
    Abstract: The present invention provides a method for treating an ocular disease such as age-related macular degeneration (AMD), diabetic retinopathy (DR) or macular edema (ME), which comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of beauvericin.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: June 15, 2021
    Assignee: ZIH YUAN TANG BIOTECHNOLOGY CO., LTD.
    Inventors: Shoei-Sheng Lee, Ming-Jai Su, Lung-Jr Lin, Chao-Min Hsu
  • Publication number: 20200316165
    Abstract: The present invention provides a method for treating an ocular disease such as age-related macular degeneration (AMD), diabetic retinopathy (DR) or macular edema (ME), which comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of beauvericin.
    Type: Application
    Filed: April 1, 2020
    Publication date: October 8, 2020
    Applicant: ZIH YUAN TANG Biotechnology Co., Ltd.
    Inventors: Shoei-Sheng LEE, Ming-Jai SU, Lung-Jr LIN, Chao-Min HSU
  • Publication number: 20200230149
    Abstract: Provided is a long-acting method for preventing or treating glucose metabolism disorders that includes administering a beta-lactam compound or a pharmaceutically acceptable salt thereof to a subject in need thereof. The method for preventing or treating glucose metabolism disorders has a long-acting effect that lasts more than two days even after medication has been stopped.
    Type: Application
    Filed: January 21, 2020
    Publication date: July 23, 2020
    Inventors: Feng-Ling Lee, Lung-Jr Lin, Jyh-Shing Hsu, Cheng-Hsien Hsu, Yen-Chun Huang, Ya-Chien Huang, Chun-Tsung Lo, Hui-Fang Liao, Yu-Wen Liu, Yu-Chi Kao
  • Publication number: 20200230105
    Abstract: Provided is a long-acting method for preventing or treating glucose metabolism disorders that includes administering a beta-lactam compound or a pharmaceutically acceptable salt thereof to a subject in need thereof. The method for preventing or treating glucose metabolism disorders has a long-acting effect that lasts more than two days even after medication has been stopped.
    Type: Application
    Filed: January 21, 2020
    Publication date: July 23, 2020
    Inventors: Feng-Ling Lee, Lung-Jr Lin, Jyh-Shing Hsu, Cheng-Hsien Hsu, Yen-Chun Huang, Ya-Chien Huang, Chun-Tsung Lo, Hui-Fang Liao, Yu-Wen Liu, Yu-Chi Kao
  • Publication number: 20190323019
    Abstract: Provided is a composition for simultaneously targeting a nucleic acid sequence and providing intron selection in cells in vitro, ex vivo or in vivo. The composition includes one or more nucleic acid molecules each including an artificial nucleic acid sequence flanked with capping sequences, and Lambda beta protein or a linear or circular vector including a nucleic acid sequence encoding the Lambda beta protein, wherein each of the capping sequences is homologous to a region in a target nucleic acid sequence, and the artificial nucleic acid sequence is an intron sequence. The present disclosure also provides a method for editing a target nucleic acid sequence in cells by introducing the composition into the cells.
    Type: Application
    Filed: December 20, 2017
    Publication date: October 24, 2019
    Inventors: Ethan HSU, Lung-Jr LIN, Yi-hua HSU